A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
China Medical University Hospital
Coherus Oncology, Inc.
Centre Oscar Lambret
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Federation Francophone de Cancerologie Digestive
Akeso
First Affiliated Hospital, Sun Yat-Sen University
Sun Yat-sen University
Institute of Oncology Ljubljana
First Affiliated Hospital Xi'an Jiaotong University
Jiangsu HengRui Medicine Co., Ltd.
Zhejiang University
University of California, San Diego
Benha University
St. Jude Children's Research Hospital
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
Mayo Clinic
Merck Sharp & Dohme LLC
Tongji University
Radiation Therapy Oncology Group
First Hospital of China Medical University
First Affiliated Hospital, Sun Yat-Sen University
Peking University
SOFIE
University of Washington
Sun Yat-sen University
University of Texas Southwestern Medical Center
Thomas Jefferson University
First Affiliated Hospital, Sun Yat-Sen University
Guangxi Medical University
Bristol-Myers Squibb
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
CHA University
University of Pittsburgh
Cedars-Sinai Medical Center
Hoffmann-La Roche
Institut National de la Santé Et de la Recherche Médicale, France
Sun Yat-sen University
Hospices Civils de Lyon
Assistance Publique Hopitaux De Marseille
Mayo Clinic
National Cancer Centre, Singapore
Shengjing Hospital
UNICANCER
Coherus Oncology, Inc.
Milton S. Hershey Medical Center
Mayo Clinic
University of Southern California